Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AZD9150 |
Synonyms | |
Therapy Description |
ISIS-STAT3rx (AZD9150) is an antisense oligonucleotide that inhibits translation of STAT3, which is often activated by receptor tyrosine kinases including FGFR, thereby preventing cell proliferation (PMID: 23935373, PMID: 30661177). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD9150 | ISIS 481464|ISIS-STAT3rx|Danvatirsen | STAT3 Inhibitor 25 | ISIS-STAT3rx (AZD9150) is an antisense oligonucleotide that inhibits translation of STAT3, which is often activated by receptor tyrosine kinases including FGFR, thereby preventing cell proliferation (PMID: 23935373, PMID: 30661177). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02499328 | Phase Ib/II | AZD9150 + Durvalumab AZD5069 + Durvalumab Durvalumab AZD9150 | Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck | Active, not recruiting | USA | ITA | ESP | DEU | BEL | 1 |
NCT02417753 | Phase II | AZD9150 | AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites | Terminated | USA | 0 |